Cost-Effectiveness of Sickle Cell Transplant vs Gene Therapy
Publication Title: Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Summary
- Question
- This study analyzed the cost-effectiveness of three treatment strategies for sickle cell disease (SCD): standard care (SOC), gene therapy (GT), and non-myeloablative haploidentical allogeneic stem cell transplantation (NMAC-HID allo-HSCT). Researchers aimed to determine which approach offers the best value in terms of quality-adjusted life years (QALYs)—a measure combining life expectancy and quality of life—across diverse healthcare systems, including the United States and several low- and middle-income countries.
- Why it Matters
SCD is a severe genetic blood disorder causing chronic pain, organ damage, and significantly reduced life expectancy. While SOC methods like hydroxyurea, blood transfusions, and pain management improve symptoms, they do not provide a cure. GT and NMAC-HID allo-HSCT are curative intent approaches, but their high costs and accessibility challenges limit widespread use. This study’s findings provide critical data to guide healthcare decisions and resource allocation, potentially improving access to effective treatments and extending life expectancy for patients globally.
- Methods
- The researchers developed a computer-based model to simulate outcomes for adults with SCD receiving SOC, GT, or NMAC-HID allo-HSCT. SOC costs and outcomes were based on real-world data, while clinical trial results informed GT and NMAC-HID allo-HSCT. Analyses considered lifetime costs, treatment efficacy, and health-related quality of life. The study extended findings to healthcare systems in the U.S., India, Nigeria, and Tanzania, adjusting for local economic factors.
- Key Findings
- NMAC-HID allo-HSCT was consistently the most cost-effective option, offering 20.1 QALYs at a cost of $1.15 million, compared to GT’s 22.1 QALYs at $2.75 million and SOC’s 14.3 QALYs at $1.22 million. Across 10,000 simulations, NMAC-HID allo-HSCT remained cost-effective in 100% of cases. GT’s price would need to be reduced by 66-71% in the U.S. to match the value of NMAC-HID allo-HSCT, and even more significantly in lower-income countries.
- Implications
- These findings suggest that NMAC-HID allo-HSCT provides a feasible, cost-effective alternative to GT for curing SCD, especially in resource-constrained settings. It could significantly reduce healthcare costs while improving patient outcomes. Policymakers, healthcare providers, and funding agencies can use this data to optimize treatment availability, prioritize investments in transplant infrastructure, and negotiate fair pricing for GT.
- Next Steps
- The researchers recommend further long-term studies to assess the durability and safety of both NMAC-HID allo-HSCT and GT. They also emphasize the need to address logistical barriers to implementation, such as donor availability for transplants and manufacturing capacity for gene therapies, particularly in low-resource settings.
- Funding Information
- This research was supported by the National Institutes of Health (NHLBI grant K01 HL175220 and NIH Research Grant CA‐016359 from the National Cancer Institute). Additional funding was provided by the NOMIS Foundation, Frederick A. DeLuca Foundation, Yale Cancer Center, and Yale Bunker Endowment.
Full Citation
Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood Journal 2026, blood.2025032290. DOI: 10.1182/blood.2025032290.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Karthik Chetlapalli
First AuthorSatoko Ito, MD, PhD
First AuthorPostdoctoral Fellow
George Goshua, MD, SM, FACP
Last AuthorAssistant Professor of Medicine (Hematology)
Additional Yale School of Medicine Authors
Media
- Photo by Getty